Thought Leaders Rank Existing and New Drugs for Rheumatology and Multiple Sclerosis in two New Reports from MedPredict

Share Article

MedPredict reports provide critical strategic insight for pharma and biotech companies with a stake in the market for diagnostics and treatments in many disease areas.

Our panelists identify their “must have” branded and generic drugs for their real-world practice in the year 2016.

MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new “Thought Leader Insight & Analysis” reports on Rheumatology and Multiple Sclerosis. Rheumatology Report Highlights:
The MedPredict Rheumatology report summarizes a thought exercise conducted with eight North American (n=5) and European (n=3) rheumatologists in September 2011. “We cover a broad range of rheumatologic conditions,” said report author Jeff Berk, “with each panelist having specific areas of specialization: rheumatoid arthritis, psoriatic arthritis, lupus, osteoporosis, gout, osteoarthritis. In this report we share each panelist’s “Fantasy Formulary”, and the strengths, weaknesses and product news for each pharmacotherapy that is mentioned.” The result of this exercise: panelists identify their “must have” branded and generic drugs for their real-world practice in the year 2016.

Companies Discussed: Abbott, Alder, Amgen, Anthera, Ardea, AstraZeneca, Biotest, Bristol-Myers Squibb, Chugai, Genmab, GlaxoSmithKline, Human Genome Sciences, Incyte, Johnson & Johnson, Lilly, Medimmune, Merck, Merck Serono, Millennium, Mitsubishi Tanabe, Neovacs, Nitec, Novartis, Onyx, Pfizer, Pharmacyclics, Regeneron, Rigel, Roche, Stryker, Vertex, UCB, Zymogenetics.

Multiple Sclerosis Report Highlights:
The MedPredict Multiple Sclerosis report highlights a series of interviews (n=7) conducted with our neurology experts in September, 2011. “Again, for this report we asked panelists to compile their 'Fantasy Formulary' in MS,” according to Berk. “This comprises the top seven therapeutics in the development pipeline they want to see available for use in the prevention/treatment of multiple sclerosis. We allowed Panelists to choose the class of drug, a specific drug (if they had a preference), the unmet needs to be addressed and the benefits that they expected their choices to deliver. The panel’s responses are just as enlightening regarding what they would NOT put on their fantasy formularies."

Companies Discussed: Acorda, Actelion, Affectis, Bayer-Schering, Biogen Idec, Boehringer-Ingelheim, Bristol-Myers Squibb, Coronado, Elan, Exelixis, Genentech/Roche, Genmab, Genzyme, GlaxoSmithKline, Kyorin, Medimmune, Merck Serono, Novartis, Nuron, Ono, Opexa, PDL Biopharma, Sanofi-Aventis, Teva, Vaccinex.

The reports may be purchased by contacting MedPredict.

About MedPredict
MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders. MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.

For more information contact:
Elizabeth Mathews


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Liz Mathews
Visit website